Literature DB >> 9437744

Structural requirements and mechanism of the pressor activity of Leu-Val-Val-hemorphin-7, a fragment of hemoglobin beta-chain in rats.

S Moisan1, N Harvey, G Beaudry, P Forzani, K E Burhop, G Drapeau, F Rioux.   

Abstract

A rat blood pressure assay was used to perform a structure-activity relationship study (SAR) of Leu-Val-Val-hemorphin-7 (LVV-H7), a fragment of hemoglobin (Hb) beta-chain, elucidate the mechanisms of its cardiovascular effects, and test its potential involvement in the pressor activity of diaspirin crosslinked Hb (DCLHb), a recently developed Hb-based oxygen carrier. The SAR study revealed that the C-terminal-Arg-Phe-amino acid sequence of LVV-H7 contained the main determinants of the pressor activity of this peptide. Drug interaction studies using various inhibitory drugs (e.g., phentolamine, clonidine, etc.) and LVV-H7 showed that the pressor effect and tachycardia elicited by LVV-H7 involved the activation of the sympathetic nervous system (SNS). Additional studies using phenytoin (sodium channel blocker), [Tic7]H7(5-7)-NH2 (putative antagonist of receptors for LVV-H7) and H7(5-7)-NH2, an amidated C-terminal fragment of LVV-H7, suggested that LVV-H7 activated the SNS by interacting with specific receptors functionally coupled with phenytoin-sensitive sodium channels. The pressor effect and tachycardia caused by LVV-H7 were potentiated by captopril, suggesting that the angiotensin converting enzyme may contribute to the inactivation of LVV-H7 in rats. The pressor activity of DCLHb, in contrast to that elicited by LVV-H7, was not affected by animal pretreatment with LVV-H7 fragments shown to inhibit the pressor effect of LVV-H7. We conclude that: 1) LVV-H7 is unlikely to mediate the pressor activity of DCLHb in rats; 2) the pressor and tachycardic activities of LVV-H7 are mediated by the SNS; 3) the C-terminal-Arg-Phe-amino acid sequence of LVV-H7 contains the chemical groups responsible for the pressor effect of this peptide in rats; 4) LVV-H7 and FMRF amide-related peptides may share the same mechanism of pressor activity in rats.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9437744     DOI: 10.1016/s0196-9781(97)00273-8

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  8 in total

Review 1.  Hemoglobin-derived peptides as novel type of bioactive signaling molecules.

Authors:  Ivone Gomes; Camila S Dale; Kimbie Casten; Miriam A Geigner; Fabio C Gozzo; Emer S Ferro; Andrea S Heimann; Lakshmi A Devi
Journal:  AAPS J       Date:  2010-09-02       Impact factor: 4.009

2.  Investigation of the structure-activity relationship in a series of new LVV- and VV-hemorphin-7 analogues designed as potential anticonvulsant agents.

Authors:  Petar Todorov; Stela Georgieva; Petia Peneva; Jana Tchekalarova
Journal:  Amino Acids       Date:  2022-01-03       Impact factor: 3.520

3.  Hemorphins act as homeostatic agents in response to endotoxin-induced stress.

Authors:  Nina Barkhudaryan; Hermine Zakaryan; Flora Sarukhanyan; Anna Gabrielyan; Dominik Dosch; Josef Kellermann; Friedrich Lottspeich
Journal:  Neurochem Res       Date:  2009-12-05       Impact factor: 3.996

4.  Molecular insights into the interaction of hemorphin and its targets.

Authors:  Amanat Ali; Bincy Baby; Soja Saghar Soman; Ranjit Vijayan
Journal:  Sci Rep       Date:  2019-10-14       Impact factor: 4.379

5.  Positive Modulation of Angiotensin II Type 1 Receptor-Mediated Signaling by LVV-Hemorphin-7.

Authors:  Amanat Ali; Abdulrasheed Palakkott; Arshida Ashraf; Isra Al Zamel; Bincy Baby; Ranjit Vijayan; Mohammed Akli Ayoub
Journal:  Front Pharmacol       Date:  2019-10-25       Impact factor: 5.810

Review 6.  Hemorphins Targeting G Protein-Coupled Receptors.

Authors:  Mohammed Akli Ayoub; Ranjit Vijayan
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-07

Review 7.  Hemorphins-From Discovery to Functions and Pharmacology.

Authors:  Przemyslaw Mielczarek; Kinga Hartman; Anna Drabik; Hao-Yuan Hung; Eagle Yi-Kung Huang; Ewa Gibula-Tarlowska; Jolanta H Kotlinska; Jerzy Silberring
Journal:  Molecules       Date:  2021-06-25       Impact factor: 4.411

8.  Camel Hemorphins Exhibit a More Potent Angiotensin-I Converting Enzyme Inhibitory Activity than Other Mammalian Hemorphins: An In Silico and In Vitro Study.

Authors:  Amanat Ali; Seham Abdullah Rashed Alzeyoudi; Shamma Abdulla Almutawa; Alya Nasir Alnajjar; Yusra Al Dhaheri; Ranjit Vijayan
Journal:  Biomolecules       Date:  2020-03-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.